Thomas Cavanaugh Files Initial Statement of Beneficial Ownership (Form 3) for Johnson & Johnson

Initial Statement of Beneficial Ownership (Form 3) Overview

Thomas Cavanaugh, serving as Executive Vice President, Worldwide Chairman, Innovative Medicine at Johnson & Johnson ($JNJ), filed an initial Form 3 on September 1, 2026, establishing his reported insider holdings.

Direct and Indirect Non-Derivative Holdings

• Direct Ownership: 71 shares of Common Stock.
• Indirect Ownership: 428 shares held through the Johnson & Johnson 401(k) Savings Plan (Johnson & Johnson Stock Fund).
• Total Common Shares: 499 shares.

Derivative Holdings & Equity Awards

Mr. Cavanaugh holds significant derivative positions awarded under the Issuer's Long-Term Incentive Plan:

1. Stock Options (Right to Buy):

   • 15,839 shares @ $243.45 (Exp: 2036-02-15)
   • 25,493 shares @ $156.15 (Exp: 2035-02-15)
   • 23,311 shares @ $157.92 (Exp: 2034-02-15)
   • 15,081 shares @ $162.75 (Exp: 2033-02-13)
   • 11,906 shares @ $165.89 (Exp: 2032-02-14)
   • 14,383 shares @ $164.62 (Exp: 2031-02-08)
   • 16,543 shares @ $151.41 (Exp: 2030-02-10)
   • Total Underlying Option Shares: 122,556 shares

2. Restricted Share Units (RSUs):

   • 2,275 RSUs (Grant date: Feb 15, 2026; 3-year annual vesting)
   • 2,097 RSUs (Grant date: Feb 15, 2025; 3-year annual vesting)
   • 965 RSUs (Grant date: Feb 15, 2024; 3-year annual vesting)
   • Total RSUs: 5,337 units (convertible 1-for-1 into Common Stock upon vesting)

Market Significance

This is a standard baseline administrative filing (Form 3) following his role designation as a Section 16 reporting officer. It involves no open-market purchase or sale activity.